4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema
Bitget2026/09/28 12:06- 4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of 4D-150 in treatment-naïve diabetic macular edema.
- Updated two-year SPECTRA results were presented, supporting durable vision and anatomical improvements with reduced need for frequent injections.
- The program advances 4D-150 into a second large retinal market, extending its late-stage pipeline beyond wet AMD.
- Regulators have discussed a potential filing strategy that relies on this single DME Phase 3 study alongside prior DME and wet AMD data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
